Outcome of myeloma patients with COVID5 19 on active lenalidomide-based therapy: 6 Does lenalidomide protect from severe 7 COVID-19?
Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% [1], [2], [3]. A recent small study report...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13586
- Acceso en línea:
- https://doi.org/10.1016/j.hemonc.2020.08.002
http://hdl.handle.net/20.500.12010/13586
- Palabra clave:
- COVID5 19
Myeloma patients
Lenalidomide-based therapy
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)